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Subcellular localizatoinFatty acid-binding proteins (FABP) play a crucial role in intracellular fatty acid transportation and
metabolism. In this study, we investigate the effects of the FABP3 Asp3Gly (D3G) polymorphism
on protein structure and function. Although the mutation did not alter protein secondary structure
or the ability to bind 1-anilinonaphthalene-8-sulfonic acid and palmitate, the intracellular stability
of the D3G mutant was signiﬁcantly decreased. Immunocytochemical analysis reveals that the
mutation alters FABP3 subcellular localization. Our results suggest that the D3G polymorphism
may impact energy metabolism and physiological functions.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Fatty acids are physiologically important energy sources, bio-
logical components, and metabolic regulators. Because fatty acids
cannot diffuse freely in the cytosol, intracellular diffusion is depen-
dent on speciﬁc carrier proteins such as fatty acid-binding proteins
(FABP). FABPs are low molecular weight (15kDa) intracellular
proteins that bind long-chain fatty acids and other hydrophobic
ligands with high afﬁnity. At least ten FABP-family molecules are
found in humans, exhibit tissue-speciﬁc expression in almost all
tissues [1], and are responsible for lipid uptake, transport, and
metabolism.
In addition to the regulation of fatty acid transport and metabo-
lism, FABPs control ligand trafﬁcking to modulate the activity of
ligand-dependent transcription factors, enzyme activity, and sig-
naling pathways in cells [2–5]. FABPs have been implicated in var-
ious diseases including obesity, diabetes, atherosclerosis, and
diverse aspects of brain function [1,6,7].Many single-nucleotide polymorphisms (SNPs) have been iden-
tiﬁed in FABPs, with some associated with metabolic syndrome [8].
The FABP2 polymorphism, Ala54Thr, expressed in the small intes-
tine was reported to be associated with insulin resistance and
increased cardiovascular risk in a patient with diabetes [9]. The
Thr94Ala variant of FABP1, predominantly expressed in the liver,
is associated with plasma lipid levels, atherothrombotic cerebral
infarction, and non-alcoholic fatty-liver disease [10].
FABP3 is expressed predominantly in heart, skeletal muscle, and
brown adipose tissue and is involved in lipid and glucose metabo-
lism [11–14]. We have previously shown that increased FABP3
expression in muscle and brown adipose tissue correlates with
obesity in mice [13,14] and that FABP3 expression improves
palmitate-induced insulin resistance in myotubes [13], establish-
ing FABP3 importance in the development of obesity. FABP3 is also
expressed in the adult brain and regulates polysaturated fatty acid
uptake and metabolism in neurons, implicating FABP3 involve-
ment in neurological functions and diseases such as Down syn-
drome, Alzheimer’s disease, schizophrenia, and autism spectrum
disorder [15,16]. Therefore, studying the consequences of FABP3
polymorphisms on protein function is essential to understanding
the causes of metabolic disorders and cerebropathy.
Over 400 FABP3 SNPs are registered in the National Center of
Biotechnology information (NCBI) dbSNP database (http://www.
ncbi.nlm.nih.gov/snp/). Although most SNPs are located in either
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been identiﬁed in the coding regions (referred to as a coding SNP or
cSNP). A cSNP resulting in an amino-acid alteration in the FABP3
protein could inﬂuence protein function leading to disease devel-
opment. Although in silico analysis using the PolyPhen algorithm
(http://coot.embl.de/PolyPhen/) revealed that an FABP3 cSNP
resulting in an Asp3Gly mutation (D3G; rs17848124) is predicted
to be ‘‘probably damaging’’ [17], there have been no structure–
function analyses of this FABP3 mutant. Here, we investigate the
effects of the D3G mutation on FABP3 and its ability to bind fatty
acids. Furthermore, we examine intracellular protein stability
and localization of FABP3 D3G in skeletal muscle cells.
2. Materials and methods
2.1. Materials
The ﬂuorescent dye, 1-anilinonaphthalene-8-sulfonic acid
(1,8-ANS), was purchased from Molecular Probes (Eugene, OR,
USA). Palmitic acid (PA) was purchased from Kanto Chemical Co.,
Inc. (Tokyo, Japan). The C2C12 myoblast cell line was purchased
from American Type Culture Collection (Manassas, VA, USA).
Plat-E cells were provided by Dr. Kamei (Kyoto Prefectural
University, Kyoto, Japan). All other chemicals were of reagent grade
and commercially available. The Escherichia coli strains DH5a and
BL21 (DE3) were used as a cloning host and for protein expression,
respectively.
2.2. Cell culture
C2C12 myoblasts were maintained in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM; Nacalai Tesque, Kyoto, Japan) containing
10% fetal bovine serum (FBS; JRH Biosciences, Lenexa, IA, USA) at
37 C in 5% CO2. Plat-E cells were maintained in DMEM supple-
mented with 10% FBS, 1 lg/ml puromycin, and 10 lg/ml blasti-
cidin, 100 U/ml penicillin, and streptomycin.
2.3. Construction of recombinant FABP3 expression vector
The cDNA encoding human FABP3 was ampliﬁed by using cDNA
from HeLa cells with primers 50-TAGCCACCATGGCGGACGCCTTTG
T-30 and 50-CTTATGTGTTGGTGGCGTGACCTGG-30. The ampliﬁed
cDNA fragment was subcloned into a pTA-2 vector (TOYOBO Co.,
Osaka, Japan) and the sequence was conﬁrmed by DNA sequencing.
The FABP3 D3G mutant was generated by using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The
primers used for mutagenesis are as follows: sense 50-CAGCATCA
CTATGGTGGGCGCTTTCCT-30; antisense 50-AGGAAAGCGCCCACCAT
AGTGATGCTG-30. Successful incorporation of the mutation was
conﬁrmed by DNA sequencing. The FABP3 wild-type (WT) and
D3G mutant cDNAs were inserted into modiﬁed pET-21b (lacking
the His-Tag) to create pET-hFABP3 and pET-hFABP3-D3G.
2.4. Expression of FABP3 proteins in E. coli
The E. coli strain BL21 (DE3) was transformed with each of the
pET-FABP3 vectors. Recombinant E. coli cells were grown in LB
broth containing 50 lg/ml ampicillin at 37 C. Protein expression
was induced by the addition of isopropyl-thio-b-D-
galactopyranoside at a ﬁnal concentration of 1 mM followed by
incubation at 37 C for 16 h. Cells were harvested by centrifugation
at 8000g for 20 min and stored at 80 C until use.
2.5. Puriﬁcation of FABP3 proteins
Cells were suspended in 50 mM Tris–HCl (pH 7.5) and disrupted
by sonication at 200 W for 20 min (Kubota Insonator 200 M,Kubota Co., Tokyo, Japan). Following centrifugation at 15000 rpm
for 20 min, the supernatant was fractionated with 40–70% ammo-
nium sulfate and the precipitate dissolved in 50 mM Tris–HCl (pH
7.5) and dialyzed against the same buffer overnight. The dialyzed
solution was applied to a HiLoad 16/10 Q Sepharose HP column
(GE Healthcare UK Ltd) equilibrated with 50 mM Tris–HCl (pH
7.5) and eluted with a linear gradient of NaCl (0–0.5 M). The eluted
proteins were concentrated using a YM-10 ultraﬁltration mem-
brane (Millipore, Bedford, MA). The concentrated proteins were
applied to a HiLoad 16/60 Superdex 75 pg column (GE Healthcare
UK Ltd) equilibrated with 50 mM Tris–HCl, 0.5 M NaCl (pH 7.5)
and eluted with the same buffer. To remove any fatty acids bound
to the FABP3 proteins, puriﬁed proteins were applied to a Lipidex
1000 column (14.5 mm i.d.  50 mm) equilibrated with 50 mM
Tris–HCl, 0.5 M NaCl (pH 7.5). The purity of FAPB3 proteins was
conﬁrmed by polyacrylamide gel electrophoresis. Puriﬁed FABP3
(1 lg) were separated on 12.5% gels and stained with Coomasie
Brilliant Blue (Nacalai tesque, Kyoto, Japan) (CBB) and protein con-
centrations calculated using extinction coefﬁcients of
14105 cmM1 at 280 nm [18].
2.6. Isoelectric focusing
Isoelectric focusing was performed using Novex IEF Gels (pH 3–
7) (Life Technologies, Paisley, UK) according to manufacturer pro-
tocol. Protein bands were stained with CBB.
2.7. Circular dichroism measurement of FABP3
Circular dichroism (CD) measurements were performed using a
Jasco J-820 spectropolarimeter. The spectrometer conditions were
as follows: spectral range 190–260 nm; 100 mdeg sensitivity;
0.1 nm resolution; 1 s response time; 100 nm/min scan rate.
Measurements were performed in 50 mM Tris–HCl, 0.5 M NaCl
(pH 7.5) at 25 C using a 2-mm light-pass-length quartz cuvette.
The protein concentrations were adjusted to 0.5 lM.
2.8. Kinetic analysis of interaction between FABP3 and 1, 8-ANS
The interaction between FABP3 and 1, 8-ANS (ANS) was evalu-
ated from ﬂuorescence change of ANS associated with its interac-
tion with FABP3. ANS was dissolved in ethanol and its
concentration was determined spectrophotometrically
(e372 = 8000 cm1 M1). Final ethanol concentrations were kept
below 1% (v/v). The ﬂuorescent intensity of ANS solution (0–
50 lM) in the presence of 1 lM FABP3 was measured at kex = 390 -
nm and kem = 435 nm with a ﬂuorescence spectrophotometer, and
the ﬂuorescence difference (DF) between in the presence and
absence of FABP3 was analyzed with following equation:
DF ¼ DFmax  ½ANSo= Kd;ANS þ ½ANSo
  ð1Þ
where DFmax and Kd,ANS were maximum ﬂuorescence change and
dissociation constant of FABP3 for ANS, respectively. The values of
DFmax and Kd,ANS were calculated by direct ﬁtting of Eq. (1) to the
data with a least-squares method performed by Gnuplot software
(ver. 4.6, http://www.gnuplot.info/).
2.9. Kinetic analysis of PA binding
FABP3 binding of PA was evaluated by changes in ﬂuorescence
associated with competitive replacement of ANS with PA. The ﬂu-
orescent intensity of solution containing 1 lM FABP3 and 50 lM
ANS was measured at kex = 390 nm and kem = 435 nm in the pres-
ence of PA at several concentrations (0–50 lM) and the data were
analyzed by the competitive binding model described below
(Scheme 1).
Scheme 1. Competitive binding of ANS and PA to FABP3.
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and PA ([PA]o), and the dissociation constants of FABP3 for ANS
(Kd,ANS) and PA (Kd,PA) are given by the following equations:
½FABP3o ¼ ½FABP3 þ ½FABP3  ANS þ ½FABP3  PA ð2Þ
½ANSo ¼ ½ANS þ ½FABP3  ANS ð3Þ
½PAo ¼ ½PA þ ½FABP3  PA ð4Þ
Kd;ANS ¼ ½FABP3½ANS=½FABP3  ANS ð5Þ
Kd;PA ¼ ½FABP3½PA=½FABP3  PA ð6Þ
[FABP3]o and [ANS]o were 1 lM and 50 lM, respectively. Under this
condition, [ANS]o  [FABP3ANS] and, therefore, Eq. (3) is approxi-
mated as [ANS]o  [ANS]. Solving these equations, [FABPANS] is
described as:
½FABP3  ANS ¼ fbþ
ﬃﬃ
ð
p
b2 4acÞg=2a ð7Þ
where a, b, and c are given as,
a ¼ ½ANSo þ Kd;ANS;
b ¼ ½ANSoðKd;PA þ ½ANSo  Kd;PA=Kd;ANS þ ½PAo  ½FABP3oÞ;
c ¼ ½ANS2o½FABP3o  Kd;PA=Kd;
The ﬂuorescent intensity is proportional to [FABP3ANS], thus:
DF=DFmax ¼ ½FABP3  ANS=½FABP3o ð8Þ
The value of Kd,PA was estimated by directly ﬁtting Eq. (8) to the
ﬂuorescent data using the previously determined values of Kd,ANS
and DFmax.
2.10. HaloTag pulse-chase experiment
A HaloTag (Promega, Madison, WI, USA) was genetically fused
to the C-terminus of FABP3 WT and D3G to create FABP3-Halo pro-
teins. The FABP3-Halos DNA fragments were inserted into theFig. 1. Puriﬁcation of FABP3 WT and D3G variants and secondary-structure analysis. (A
(middle), and FABP3 D3G (right). (B) Measurement of isoelectric point (pI). Markers (left),
FABP3 D3G.retroviral expression vector pMXs-Puro (pMX-WT-Halo and
pMX-D3G-Halo). Plat-E cells were transfected with pMX-WT-
Halo and pMX-D3G-Halo and the culture media was collected after
48 h. C2C12 cells were infected with the WT-Halo and D3G-Halo
retroviral vectors and selected with 1 lg/ml puromycin for 3 days.
C2C12 myoblast cells stably expressing WT-HaLo and D3G-Halo
were pulse-labeled with 1 lM HaloTag TMR Ligand (Promega,
Madison, WI, USA) for 15 min. After washing four times with
DMEM, cells were incubated in DMEM with 10% FBS for 72 h,
washed twice with PBS, lysed in 150 ll of SDS sample buffer, and
subjected to SDS–PAGE. The HaloTag TMR Ligand-labeled FABP3
WT and D3G were visualized using a ﬂuorescence image analyzer,
LAS4000 (GE healthcare), and analyzed using ImageJ (Rasband,
W.S., ImageJ, U.S. National Institutes of Health, Bethesda,
Maryland, USA, http://imagej.nih.gov/ij/, 1997–2014). Half-life
(t1/2) was calculated by direct ﬁtting of the theoretical equation
(Eq. (9)) to the data of three independent experiments:
FABP3 Remaining ð%Þ ¼ 100 ð1=2Þft=ðt1=2Þg ð9Þ2.11. Analysis of subcellular localization
C2C12 cells were infected with adenovirus-expressing FABP3
WT and D3G at a multiplicity of infection of 200 for 24 h. After
48 h, cells were subcultured on ibidi l-Slides (Integrated
BioDiagnostics), then after an additional 24 h, ﬁxed with 4%
paraformaldehyde in PBS for 30 min at room temperature and
washed twice with PBS. Fixed cells were permeablized with 0.4%
Triton X-100 in PBS for 10 min and blocked with Blocking One
Histo (Nacalai Tesque, Kyoto, Japan). Cells were then incubated
with Mouse anti-human FABP3 monoclonal antibody (Hycult,
Netherland) at a dilution of 1:100 in 5% Blocking One Histo at
4 C overnight and incubated with the secondary antibody, Goat
anti-Rabbit IgG Alexa Fluor 488 (Molecular Probes, Leiden,
Netherlands) at a dilution of 1:1000 in 5% Blocking One Histo for
1 h at room temperature. Nuclei were stained with DAPI
(Dojindo, Kumamoto, Japan) and examined using a BIOREVO
BZ-9000 ﬂuorescence microscope (Keyence, Osaka, Japan).
2.12. Statistical analysis
Data were expressed as means ± standard error of the mean
(S.E.M.). Signiﬁcant differences between groups were assessed by
Student’s t-test.) Molecular weight determination using SDS–PAGE. Size markers (left), FABP3 WT
FABP3WT (middle), and FABP3 D3G (right). (C) CD-spectra of 0.5 lM FABP3WT and
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3.1. Puriﬁcation of FABP3 proteins from E. coli
Expression and puriﬁcation of recombinant human FABP3 WT
and D3G was undertaken as described in Materials and Methods.
To ensure that the puriﬁed FABP3 variants were devoid of residual
bound fatty acids, proteins were delipidated prior to binding
experiments [19]. Puriﬁed FABP3 variants are shown in Fig. 1A.
Aspartate is a polar amino acid and has a negative charge at phys-
iological pH, while glycine is a non-polar amino acid with no
charge. Therefore, the D3G Asp-Gly substitution may result in a
more positively-charged protein as compared to WT. Isoelectric
focusing experiments to examine the impact of this mutation on
surface charge were performed, resulting in estimated pI values
for WT and D3G of 5.2 and 6.0, respectively (Fig. 1B). CD spectra
were then measured to investigate the presence of secondary-
structure differences between FABP3 WT and D3G, revealing no
measureable differences observed between the two variants
(Fig. 1C). These results indicate that the Asp-Gly substitution does
not signiﬁcantly impact secondary structure or the overall confor-
mation of FABP3, but does contribute to an alteration in surface
charge.
3.2. Binding properties of recombinant FABP3 variants
To elucidate the impact of mutations on ligand binding, we per-
formed binding assays using FABP3 WT and D3G in the presence ofFig. 2. Lipid-binding capability of FABP3 WT and D3G variants. (A) 1,8-ANS binding
to FABP3 WT and FABP3 D3G. (B) Displacement of 1,8-ANS from FABP3 WT and
FABP3 D3G by palmitate. FABP3 WT and FABP3 D3G are shown as closed and open
circles, respectively. Kd values were calculated from at least four independent
experiments.1,8-ANS, a ﬂuorescent probe with afﬁnity for the FABP3
ligand-binding pocket [20,21]. The apparent dissociation constants
(Kd) associated with 1,8-ANS binding to FABP3 WT and D3G are
5.69 ± 0.36 lM and 6.24 ± 0.19 lM, respectively, indicating no sig-
niﬁcant difference in binding afﬁnity for 1, 8-ANS between the two
variants (Fig. 2A). To investigate differences in afﬁnity between
FABP3 WT and D3G for fatty acid, PA binding was measured using
a competitive-displacement assay. Competition curves indicate
that 1,8-ANS ﬂuorescence decreased relative to increasing concen-
trations of PA (Fig. 2A). The Kd values associated with PA binding
are 1.16 ± 0.08 lM and 1.28 ± 0.10 lM for FABP3 WT and D3G,
respectively, and are in agreement with those previously published
[22]. These results indicate that the Asp-Gly mutation does not sig-
niﬁcantly impact FABP3 ligand binding.
3.3. D3G mutation decreases FABP3 stability in C2C12 myoblast cells
To investigate whether the Asp-Gly mutation contributes to
FABP3 intracellular stability in mammalian cells, we performed
HaloTag-mediated pulse-chase experiments [23]. Since FABP3 is
expressed mainly in cardiac and skeletal muscle cells, we used
mouse myoblast C2C12 cells for this experiment. Our results
revealed increased degradation of the FABP3 D3G mutants as com-
pared to WT in C2C12 myoblast cells (Fig. 3). The half-lives of FABP
WT and D3G were calculated to be 45.0 ± 1.9 h and 37.2 ± 1.9 h,
respectively, indicating that the Asp-Gly mutation reduces FABP3
intracellular stability.Fig. 3. Protein stability of FABP3 WT and D3G variants in C2C12 myoblast cells.
Pulse-chase experiments were performed using C2C12 cells expressing HaloTag
FABP3 variants. (A) FABP3 WT-Halo and FABP3 D3G-Halo were labeled with
HaloTag TMR Ligand and chased for indicated time. (B) Time courses for clearance
of labeled FABP3 WT-Halo and FABP3 D3G-Halo are shown as closed and open
circles, respectively. Results represent the mean ± S.E.M. of three independent
experiments, **P < 0.01 vs. WT.
Fig. 4. Subcellular localization of FABP3 WT and D3G variants in C2C12 myoblast cells. C2C12 cells were infected with adenoviral vectors expressing FABP3 WT and FABP3
D3G. (A) Subcellular localization of FABP3. Cells were classiﬁed as follows; C > N, FAPB3 concentration is higher in the cytosol than that observed in the nucleus; C@N, FABP3
concentration in the cytosol is similar to that observed in the nucleus; C < N, FABP3 concentration is lower in the cytosol than that observed in the nucleus. Cell images and
percentages of the classiﬁed cells are shown. At least 100 cells in 4–6 different images were quantiﬁed. Results represent the mean ± S.E.M., *P < 0.05, **P < 0.01 vs. WT. (B)
Putative structure of the FABP3 protein shown as ribbon model (Protein Data Bank ID, 3WBG). Asp3 (red), putative NES (L67, L97, L92, blue) and NLS (K22, R31, Q32, green)
residues and 1,8-ANS (orange) are shown as sticks. The structure was generated using Discovery Studio 4.1 (Accelrys, San Diego, CA).
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Finally, we examined the subcellular localization of FABP3 WT
and D3G in C2C12 myoblast cells. To evaluate localization to either
the cytosol or the nucleus, stained cells were classiﬁed into three
groups according to their ﬂuorescence intensity: C > N, the ﬂuores-
cence intensity of FAPB3 is higher in the cytosol than that observed
in the nucleus; C@N, the ﬂuorescence intensity of FABP3 in the
cytosol is equal to that observed in the nucleus; C < N, the ﬂuores-
cence intensity of FABP3 in the cytosol is lower than that observed
in the nucleus (Fig. 4A). The Asp-Gly mutation resulted in a
decrease in the percentage of cells classiﬁed as C > N from 36.3%
to 15.7%, while the percentage of cells classiﬁed as C < N and
C@N increased from 5.2% to 13% and 58.5% to 72.0%, respectively.
These results indicate that the Asp-Gly mutation inﬂuences
FABP3 subcellular localization.
4. Discussion
The amino-acid alterations in FABPs impact their physiological
functions. The Ala54Thr mutant of FABP2 shows a 2-fold greater
afﬁnity for fatty acid than FABP2 WT [24,23]. The increased afﬁnity
for fatty acid results in higher levels of fatty-acid uptake and lower
peripheral insulin sensitivity [25]. In the case of FABP1, a Thr94Ala
mutation alters protein secondary structure, stability, and ligand
activation of PPARa transcriptional activity in human hepatocytes
[10]. Here, we have examined the impact of an Asp3Gly mutation
on FABP3 structure and function.
Although the mutation resulted in changes to FABP3 surface
charge, no difference was observed in secondary structure between
the FABP3WT and D3G variants, indicating that Asp3 does not con-
tribute to the FABP3 structure. This mutation also did not alter the
ability of FABP3 to bind 1,8-ANS and PA, which may be explained
by the location of Asp3 relative to the ligand-binding pocket and
its evident minimal impact on overall structure.
The results of in silico analysis of FABP3 D3G were not corre-
sponded. Shimamoto et al. analyzed the impact of the D3G muta-
tion on FABP3 biological function using the in silico tools SIFT
(http://blocks.fhcrc.org/sift/SIFT.html), PolyPhen-2 (http://genet-
ics.bwh.harvard.edu/pph2/), and Pmut (http://mmb2.pcb.ub.es:8080/PMut/) [15]. The analyses indicated that the effects of the
mutation were ‘tolerable’ according to SIFT, ‘benign’ according to
PolyPhen-2, and ‘neutral’ according to Pmut, and that the overall
impact on FABP3 structure and function was minimal. However,
using the PolyPhen algorithm, Maekawa et al. predicted that the
FABP3 D3G mutation results in elimination of a salt bridge
between Asp3 and Lys45 that might adversely impact protein sta-
bility [17]. Our results revealed that the intracellular stability of
FABP3 D3G was decreased relative to WT in C2C12 myoblast cells,
suggesting that Asp3 may contribute to protein stability.
Additionally, variations in intracellular localization between
FABP3 WT and D3G were observed. Amino acid sequences identi-
fying nuclear export signal (NES) or nuclear localization signal
(NLS) have not been identiﬁed in FABP3. Although neither NES
nor NLS sequences have been detected in the primary sequence
of FABP [21], residues L66, L86, L91, and K21, R30, K31 qualify as
NES and NLS sequences, respectively. Similarly, FABP3 residues
L67, L87 and L92 mimic NES sequences and, while the typical
NLS sequence is not fully conserved in FABP3, the residues K22,
R31 and Q32 share similar properties with NLS sequences
(Fig. 4B). In our analysis, the FABP3 D3G exhibited twofold higher
levels of nuclear localization relative to FABP3 WT. Also, FABP3
D3G localized to the cytosol 50% less often than FABP3 WT.
Given the proximity of Asp3 relative to the putative NES sequence
(Fig. 4B), the Asp-Gly mutation may inhibit interactions between
FABP3 and exportins such as CRM1, which transports FABP4 from
the nucleus to the cytosol [21]. These results suggest that increased
FABP3 D3G nuclear localization may be caused by a reduction in
the capability of FABP3 to be exported from the nucleus rather
than increases in cytosol-to-nucleus translocation. Likewise,
decreased FABP3 stability observed in the cytosol could impact dif-
ferences in subcellular localization between FABP3 variants.
In summary, the FABP3 D3G mutation resulted in altered pro-
tein stability and localization in myoblast cells. Although there
were minimal differences in ligand-binding capability between
FABP3 D3G and WT, this mutation could inﬂuence other FABP3
functions including ligand transport to target organelles, enzyme
regulation, or ligand-dependent transcription-factor activation.
Given the importance of FABP3 in lipid metabolism, the FABP3
D3G polymorphism may also impact energy metabolism and brain
T. Kusudo et al. / FEBS Letters 589 (2015) 2382–2387 2387function, however, the speciﬁc association of this mutation with
disease remains unclear. A large cohort study would be required
to clarify connections between the FABP3 D3G polymorphism
and certain disorders.
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